November 24 (SeeNews) - Bosnian pharmaceuticals producer Bosnalijek [SAJ:BSNLR] said on Thursday its net profit soared to 22.4 million marka ($11.9 million/11.5 million euro) in the first nine months of 2022 from 1.1 million marka booked in the like period of last year.
Operating income grew 31% on the year, reaching 97.1 million marka in the January-September period, whereas operating costs rose 11.5% to 88.8 million marka, Bosnalijek said in a filing to the Sarajevo Stock Exchange (SASE).
Bosnalijek's financial income jumped to 23.2 million marka in the period under review, from 8.1 million marka reported for the first nine months of 2021. Financial costs went up 23% year-on-year to 3.7 million marka in the nine months under review.
The company's shares last traded on the SASE on November 15, when they closed 0.03% at 29.7 marka.
Bosnalijek is the largest pharmaceuticals company in Bosnia and Herzegovina.
(1 euro = 1.95583 marka)